Beyond Keytruda: Inside Merck’s High-Stakes Pivot to a New 'Cornerstone' Cancer Therapy

Merck & Co. presents promising ASCO 2026 data for sac-TMT, an antibody-drug conjugate designed to offset the looming Keytruda patent cliff. Explore the Phase 3 lung cancer results, the TROP2 competitive landscape, and analyst perspectives on the drug's global viability.